Amphista Targeted Glue Data Shows Tumor Regression
CAMBRIDGE, UK, April 24, 2026 Amphista Therapeutics has unveiled new preclinical data demonstrating the therapeutic potential of its SMARCA2...
AACR 2026
Advertisement
Akeso Cadonilimab Combo Shows Strong Survival in Pancreatic Cancer
Hong Kong, April 20, 2026 In a significant breakthrough in oncology immunotherapy, Akeso, Inc. has announced promising Phase II...
Rznomics RZ-001 Shows Strong HCC Clinical Data AACR
SAN DIEGO, Calif., April 19, 2026 Rznomics Inc. announced encouraging interim clinical results from its ongoing study of RZ-001,...
Enara Bio Showcases ENA101 Cancer Immunotherapy at AACR
OXFORD, UK, April 20, 2026 Enara Bio announced the presentation of breakthrough preclinical data for ENA101, its first-in-class bispecific...
Verismo SynKIR-110 Shows Phase 1 Safety in Solid Tumors
PHILADELPHIA, April 20, 2026 Verismo Therapeutics has reported promising initial Phase 1 clinical data from its STAR-101 trial, evaluating...
Advertisements
Revolution Medicines Reports Breakthrough Zoldonrasib Data
REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...
Synthetic Design Lab Unveils Logic-Gated ADC Platform
SAN CARLOS, Calif., April 20, 2026 Synthetic Design Lab announced the first public presentation of its SYNTHBODY™ platform at...
Nanobiotix Reports Nanoprimer Breakthrough at AACR 2026
PARIS, France & CAMBRIDGE, USA, April 20, 2026 Nanobiotix has unveiled promising preclinical data demonstrating that its Nanoprimer technology...
Abbott Cancerguard Advances Multi-Cancer Detection Data
ABBOTT PARK, Ill., April 17, 2026 Abbott has unveiled new data at the AACR Annual Meeting 2026 demonstrating significant...
Marengo Reports Phase 2 Breast Cancer Data at AACR
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics, Inc. announced late-breaking Phase 2 clinical results for its investigational immunotherapy invikafusp...
Advertisement
